Femasys Inc (FEMY) - News Archive

In a significant stride toward enhancing women s health and reproductive rights, Femasys Inc. (NASDAQ: FEMY) has announced a notable initial order valued at approximately $500,000 USD for its innovative FemBloc Permanen...

In an exciting development within the healthcare sector, Femasys Inc., a recognized leader specializing in innovative women s healthcare solutions, has announced a groundbreaking partnership with Medical Electronic Syst...

In today’s evolving healthcare landscape, women s health, particularly in reproductive medicine, has emerged as a focal point of innovation and investment. Femasys, Inc. a prominent player in this sector, has recently b...

Femasys Inc. an innovative leader in women’s health, has announced the successful peer-reviewed publication of data from its prospective, multicenter pivotal trial evaluating the FemaSeed infertility treatment. The tria...

Femasys Inc. and the FemBloc Patent: A Significant Step ForwardFemasys Inc. a company committed to providing innovative solutions in women s healthcare, recently announced the issuance of a U.S. patent covering its FemB...

In a significant step forward for women’s reproductive health, Femasys, Inc. (Nasdaq: FEMY), a leading biomedical company headquartered in Atlanta, has announced the successful completion of its initial commercial FemaS...

In a significant development within the realm of women s reproductive healthcare, Femasys Inc. has announced the establishment of vital distribution partnerships aimed at bringing its innovative FemaSeed infertility tre...

Femasys Expands European Footprint with Strategic Distribution Partnerships, Despite Financial ChallengesFemasys Inc. a notable player in the healthcare technology sector, has recently secured strategic distribution par...

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec, an Innovative Diagnostic Solution for Fallopian Tube Check In a significant advancement for women s health, Femasys Inc. a pioneering force in female healthcar...

Breaking Through: Femasys Secures CE Mark Approval for Women s Health Innovations When it comes to addressing the significant unmet needs in women s healthcare, Femasys Inc. stands at the forefront. The Atlanta-based bi...

Femasys CEO Meets with White House Gender Policy Council to Discuss Revolutionary Women s Reproductive Health Products, Impacting Share Price Negatively in Q2 2024In a groundbreaking development, Kathy Lee-Sepsick, the...

Femasys Inc, a leading healthcare company, recently announced the addition of experienced professionals to its commercial management team. The new hires are expected to drive strategic initiatives and launch efforts at...

Femasys Inc., a leader in gynecological research and innovation, has recently announced positive topline data from a pivotal trial involving its FDA-cleared FemaSeed for the treatment of infertility. The trial demonstra...

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution, Paving the Way Forward for Broader Availability and Cost-Effective Alternatives to IVFIn a significant miles...

Femasys FemaSeed: A Timely Solution in the Face of IVF UncertaintyIn recent years, infertility has become a growing concern around the world, affecting millions of couples who dream of starting a family. In the United S...

In recent developments, Femasys Inc. has launched its pivotal trial for FemBloc - a revolutionary medical device aimed at providing a minimally invasive and reversible contraceptive solution for women. The trial s enrol...

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford MedicineStanford Medicine, renowned for its long-standing dominance in gynecological research and groundbreaking innovations, has become the second academ...

Femasys Inc., a leading medical technology company, has recently achieved a significant milestone by completing the enrollment of the FemaSeed pivotal trial. This achievement positions the company for a successful comme...